Johnson & Johnson Cardiovascular/Metabolism/Other revenue
Cardiovascular/Metabolism/Other revenue at Johnson & Johnson came to $849.0M for the quarter to 27 Sep 2026, down 5.6% from a year earlier.
As Johnson & Johnson reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 21 Oct 2026.
By quarter
| Period ending | Cardiovascular/Metabolism/Other revenue | Change on a year | Filed |
|---|---|---|---|
| 27 Sep 2026 | $849.0M | down 5.6% | 21 Oct 2026 |
| 28 Jun 2026 | $889.0M | down 4.4% | 23 Jul 2026 |
| 29 Mar 2026 | $876.0M | down 13.5% | 22 Apr 2026 |
| 28 Dec 2025 | $936.0M | — | 11 Feb 2026 |
| 28 Sep 2025 | $899.0M | — | 22 Oct 2025 |
| 29 Jun 2025 | $930.0M | — | 24 Jul 2025 |
| 30 Mar 2025 | $1.0B | — | 23 Apr 2025 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Johnson & Johnson: MedTech worldwide operational sales (change on a year) · Oncology revenue · Immunology revenue · Neuroscience revenue · Cardiovascular revenue · Pulmonary Hypertension revenue · Infectious Diseases revenue · Shockwave revenue · Innovative Medicine revenue · MEDTECH revenue · United States revenue · Non-US revenue · Europe revenue · Asia-Pacific, Africa revenue · Western Hemisphere, excluding U.S. revenue · financial statements
Every KPI and segment of JNJ, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
